Analysts Set Fulgent Genetics, Inc. (NASDAQ:FLGT) PT at $32.00

Fulgent Genetics, Inc. (NASDAQ:FLGT) has been given a consensus rating of “Hold” by the five ratings firms that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation and two have issued a buy recommendation on the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $32.00.

A number of brokerages have commented on FLGT. Raymond James Financial reaffirmed an “outperform” rating and issued a $36.00 price target on shares of Fulgent Genetics in a research note on Friday, November 14th. Zacks Research cut shares of Fulgent Genetics from a “strong-buy” rating to a “hold” rating in a report on Monday, February 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Fulgent Genetics in a research note on Thursday, January 22nd. Piper Sandler upped their price target on shares of Fulgent Genetics from $21.00 to $30.00 and gave the company a “neutral” rating in a report on Tuesday, November 11th. Finally, Wall Street Zen cut shares of Fulgent Genetics from a “hold” rating to a “sell” rating in a research report on Saturday.

Hedge Funds Weigh In On Fulgent Genetics

Several hedge funds and other institutional investors have recently modified their holdings of FLGT. Farther Finance Advisors LLC grew its stake in shares of Fulgent Genetics by 69.3% in the fourth quarter. Farther Finance Advisors LLC now owns 1,339 shares of the company’s stock worth $35,000 after purchasing an additional 548 shares during the last quarter. Kestra Advisory Services LLC bought a new position in Fulgent Genetics during the 4th quarter valued at approximately $35,000. Caitong International Asset Management Co. Ltd raised its position in Fulgent Genetics by 214.6% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,834 shares of the company’s stock valued at $48,000 after purchasing an additional 1,251 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in Fulgent Genetics in the 2nd quarter worth approximately $49,000. Finally, Flagship Harbor Advisors LLC purchased a new stake in Fulgent Genetics in the 4th quarter worth approximately $56,000. 48.06% of the stock is owned by institutional investors.

Fulgent Genetics Trading Down 3.4%

Shares of NASDAQ:FLGT opened at $14.38 on Wednesday. The stock’s 50-day moving average price is $23.89 and its 200-day moving average price is $24.52. Fulgent Genetics has a 12-month low of $13.46 and a 12-month high of $31.04. The stock has a market capitalization of $449.10 million, a P/E ratio of -7.34 and a beta of 0.94.

Fulgent Genetics (NASDAQ:FLGT) last released its earnings results on Friday, February 27th. The company reported $0.16 earnings per share for the quarter, beating analysts’ consensus estimates of $0.02 by $0.14. The company had revenue of $83.34 million during the quarter, compared to analyst estimates of $85.38 million. Fulgent Genetics had a negative return on equity of 2.22% and a negative net margin of 18.75%.Fulgent Genetics has set its FY 2026 guidance at -1.450–1.450 EPS. As a group, research analysts predict that Fulgent Genetics will post -0.85 EPS for the current year.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc (NASDAQ: FLGT) is a California-based company specializing in high-complexity genetic testing and diagnostic services. Operating from its headquarters in Temple City, Fulgent leverages next-generation sequencing (NGS) technologies and advanced bioinformatics to deliver a broad range of clinical and research assays. The company’s infrastructure includes CAP- and CLIA-certified laboratories, enabling it to process large volumes of samples with rapid turnaround times.

Fulgent’s product portfolio encompasses hereditary cancer panels, rare disease and neuromuscular disorder testing, pharmacogenomic screenings, non-invasive prenatal tests, and infectious disease assays including COVID-19 diagnostics.